Impact of a Reduction in Susceptibility Testing for Pseudomonas aeruginosa in a Cystic Fibrosis Program

Am J Respir Crit Care Med. 2020 Jan 1;201(1):114-116. doi: 10.1164/rccm.201903-0576LE.
No abstract available

Publication types

  • Letter

MeSH terms

  • Anti-Bacterial Agents / therapeutic use*
  • Cystic Fibrosis / drug therapy*
  • Cystic Fibrosis / microbiology*
  • Humans
  • Microbial Sensitivity Tests
  • Pseudomonas Infections / drug therapy*
  • Pseudomonas aeruginosa / drug effects*

Substances

  • Anti-Bacterial Agents